Patents by Inventor Gergely Szakács

Gergely Szakács has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FLUORESCENT DYE ACCUMULATION ASSAY
    Publication number: 20200284797
    Abstract: ABC multidrug transporters are key players in cancer multidrug resistance and in general xenobiotic elimination, thus their functional assays provide important tools for research and diagnostic applications. It has been found that in cells expressing functional ABCG2, ABCB1, or ABCC1 transporters, cellular PG fluorescence is strongly reduced. The invention relates to methods and uses of fluorescein derivative ester compounds of formula Ia which are analogs of PG for assessing ABC transporter activity of ABC multidrug transporters. The present accumulation assay is a novel tool for the parallel determination of the function of the multidrug transporters, in particular ABCG2, ABCB1, and ABCC1. The assay is applicable for diagnostic purposes and also allows the selection, separation and culturing of selected cell populations expressing such transporters.
    Type: Application
    Filed: October 25, 2018
    Publication date: September 10, 2020
    Inventors: Edit SZABÓ, Dóra KOVÁCS-TÜRK, Ágnes TELBISZ, Nóra KUCSMA, Tamás HORVÁTH, Gergely SZAKÁCS, László HOMOLYA, Balázs SARKADI, VÁRADY György
  • MDR-reversing 8-hydroxy-quinoline derivatives
    Patent number: 10744127
    Abstract: The present invention is related to 8-hydroxy-quinoline derivatives having multidrug-resistance reversing activity with improved selectivity and increased cytotoxicity towards multidrug-resistant cancer cells, preparation thereof and use of the same in the treatment of cancer, especially multidrug-resistant variants thereof.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: August 18, 2020
    Assignee: Magyar Tudományos Akadémia Természettudományi Kutatóközpont
    Inventors: Gergely Szakács, Tibor Soós, Roberta Ferenczi-Palkó, András Füredi, Szilárd Tóth, Dóra Türk, Veronika Pape, Ferenc Fülöp, István Szatmári, György Dormán
  • MDR-REVERSING 8-HYDROXY-QUINOLINE DERIVATIVES
    Publication number: 20190151306
    Abstract: The present invention is related to 8-hydroxy-quinoline derivatives having multidrug-resistance reversing activity with improved selectivity and increased cytotoxicity towards multidrug-resistant cancer cells, preparation thereof and use of the same in the treatment of cancer, especially multidrug-resistant variants thereof.
    Type: Application
    Filed: April 5, 2017
    Publication date: May 23, 2019
    Applicant: Magyar Tudományos Akadémia Természettudományi Kutatóközpont
    Inventors: Gergely SZAKÁCS, Tibor SOÓS, Roberta FERENCZI-PALKÓ, András FÜREDI, Szilárd TÓTH, Dóra TÜRK, Veronika PAPE, Ferenc FÜLÖP, István SZATMÁRI, György DORMÁN
  • COMPOUNDS WITH MDR1-INVERSE ACTIVITY
    Publication number: 20100316655
    Abstract: Disclosed herein are drug compounds that have MDR-inverse activity and thus are effective against multidrug-resistant cells. Exemplary compounds disclosed herein have the structure: Examples of the disclosed compounds have been found to have, inter alia, efficacy in directly treating multidrug resistant cells, rendering multidrug resistant cells susceptible to other chemotherapeutics and in some instances reversing multidrug resistance.
    Type: Application
    Filed: February 10, 2009
    Publication date: December 16, 2010
    Inventors: Matthew D. Hall, Michael M. Gottesman, Jennifer L. Hellawell, Joseph A. Ludwig, Henry M. Fales, Noeris K. Salam, Gergely Szakács
  • Methods for the Identification and Use of Compounds Suitable for the Treatment of Drug Resistant Cancer Cells
    Publication number: 20080214606
    Abstract: The present invention relates to novel methods for the identification of compounds useful for the treatment of drug resistance, and to novel treatment methods using the identified compounds.
    Type: Application
    Filed: June 16, 2005
    Publication date: September 4, 2008
    Applicant: The Government of the United States of America as represented by The Secretary of the Dept. of .....
    Inventors: Gergely Szakacs, Jean-Phillipe Annereau, Samir Lababidi, Michael M. Gottesman, John Weinstein
  • Screening system based on expression of abcg2 half transporter protein
    Publication number: 20040175762
    Abstract: The overexpression of an ABC half-transporter, ABCG2 (MXR/BCRP) transporter causes multidrug resistance in tumors. The present invention is based on the in vitro expression of the ABCG2 protein in insect cells as an expression system free of other, closely related, functional ABC transporters. In particular, the invention is related to a method for testing drugs for their effect on ABCG2 protein, method for the expression of active ABCG2, isolated ABCG2 homooligomers, preferably homodimers and uses thereof for testing drugs. The invention is further related to cell membrane preparations and cells, preferably insect cells comprising active ABCG2 and reagent kits for testing drugs for their effect on an ABCG2 half transporter protein. The invention is also related to a method for identifying ABCG2 activity in a biological sample, utilizing its substrate/inhibitor specificity.
    Type: Application
    Filed: January 16, 2004
    Publication date: September 9, 2004
    Inventors: Csilla Ozvegy, Gergely Szakacs, Andras Varandi, Zoltan Nagy